QuidelOrtho has come together to shape the future of in-vitro diagnostics, uniting strengths to offer unparalleled service and innovation.
The QuidelOrtho merger is a testament to a shared commitment to furthering diagnostic precision, ensuring better patient outcomes, and leading the world towards a healthier tomorrow.
We are driven to transform diagnostic data into answers, understanding and action.
We provide access to answers across the entier diagnostics continuum. With our help, patients, clinicaians and cummities can spot trends sooner, respond quicker and chart the course ahead with greater accuracy and confidence.
Our innovations have changed diagnostics. From our dry chemistry that delivers testing access where teh is none, to respiratory testing and tracking breadkthorughs that offer much needed intelligence in a world of uncertainty, we're at the forefront of diagnostic science and care.
We know diagnostics has the power to unlock a healthier future for all. For over 80 year, we've relentlessly pursued the unknown with a passion and purpose to improve health. And we'll continue to raise the bar, bringing clarity and insight in setting from home to hospital, lab to clinic.
Turning complex data into actionale health insights is more than a mission. We understand patients, their families, clinicians and care providers worldwide depend on our products for answers that save lives- and we innovate every day to exceed their expectations.
We proudly continue our legacy of innovation, with industry-leading expertise in immunoassay and molecular testing and award-winning solutions in clinical labs and transfusion medicine.
You’ve probably met a few of us, but you might not know us all. With a shared talent for diagnostic speed and accuracy, as well as a common belief system of service, loyalty and care, we bring diagnostic insights to more places – even yours.
Point-of-Care-Testing
A continuum of diagnostic immunoassays including visually read rapid lateral flow tests and analyzer read fluorescent immunoassays that interpret and display results. The point-of-care assays accommodate the needs of differing healthcare settings from the physician office to emergency department, from hospital bedside to the laboratory.
Assays include:
• High Sensitivity Troponin I
• Cardiac Marker Panels
• TOX Drug Screens
• Influenza & SARS
• C.difficile
• Camplyobactor
• Many more assays
Clinical Chemistry
VITROS Solutions, from standalone chemistry and immunoassay systems to integrated systems and fully automated solutions, that deliver consistently fast, accurate and reliable results that expedite treatment decisions and improve patient care. Our proprietary dry chemistry technology enables a long performance and calibration stability, providing precise and accurate results without the need for water.
• Integrated systems
• Immunoassay
• Automation solutions
Immunohematology
We share the vital mission of donor testing center’s and pre-transfusion labs to enable the reliable and timely access to safe blood products for patients everyday. Blood bank solutions for donor testing and pre-transfusion screening to improve your lab efficiency, workflow and output.
• OrthoVision automated solutions
• Semi-automated solutions
• Comprehensive assay menu for pre-transfusion testing
• Workflow management solutions
• Vitros immunodiagnostics for infectious disease testing
Over the years
2020s
2025
Launches QuidelOrtho® Results Manager™ System, strengthening informatics capabilities across the diagnostics portfolio to address the growing demands of modern laboratories
2024
Receives FDA 510(k) clearance for the QuickVue® COVID-19 Test for at-home testing
2023
QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA
QuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS-CoV-2 Antigen+ FIA
QuidelOrtho Receives De Novo Classification for two SARS-CoV-2 Antibody tests: VITROS® Immunodiagnostics Products Anti-SARS-CoV-2 Total Test and VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 IgG test
2022
Health Canada Grants License for Quidel® TriageTrue® High-Sensitivity Troponin l Test to Aid in the Diagnosis of Myocardial Infarction
Quidel Corporation and Ortho Clinical Diagnostics unite as QuidelOrtho with an 80-year history of innovation
2021
Quidel recieves FDA EUA for QuickVue® At-Home OTC COVID-19 Test
Ortho begins trading on Nasdaq under the symbol OCDX
2020
Quidel recieves FDA EUA for Sofia® 2 SARS Antigen FIA, the first rapid antigen test for COVID-19
Ortho launches two VITROS® SARS-CoV-2 antibody tests, receiving CE Marks and among the first FDA EUAs for high-volume COVID-19 testing; SARS-CoV-2 antigen test follows in 2021
2010s
2017
Quidel acquires Triage® cardiac and toxicology product line
2016
Ortho receives FDA clearance for Ortho Vision®
2015
Ortho receives FDA clearance for VITROS® automated solutions
2014
The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson
2013
Ortho launches Ortho® Workstation
2011
Quidel receives FDA clearance for Sofia®
2010
Quidel acquires Diagnostic Hybrids, Inc.
2000s
2003
Ortho launches Ortho ProVue®, the first fully automated immunohematology sytem for use with the ID-Micro Typing SystemTM (ID-MTS) Gel Test in North America
2000
Ortho receives first FDA approval for automated random access VITROS® ECiQ Immunodiagnostic System.
1990s
1999
Quidel receives FDA clearance for world's first rapid diagnostics flu test, QuickVue® Influenza Test A+B
1998
Ortho introduces Ortho SummitTM, the first truly automated blood and plasma screening system in the U.S.
1997
Ortho Clinical Diagnostics is formed following the 1994 Johnson & Johnson acquisition of Kodak's diagnostics business
1991
Quidel begins trading on Nasdaq under the symbol QDEL
1980s
1989
Ortho introduces the first hepatitis C antibody test
1985
Quidel receives FDA clearance for Strep A testing
1983
Quidel introduces the first commerical product for pregnancy testing
1970s
1979
Quidel Corporation is founded in San Diego, CA
1978
Kodak Clinical Diagnositics introduces patented thin-film dry slide technology
1940s
1947
Ortho develops the first blood bank anti-D test for the clinical market
1930s
1939
Ortho Products, Inc. is formed in Linden, N.J. as a divison of Johnson & Johnson
Ensuring reliability and efficiency after installation isn't an afterthought – it's a central tenet of our ethos. Recognised with global awards, QuidelOrtho’s steadfast commitment ensures that laboratories can operate seamlessly. In the critical landscape of diagnostics, where every test result has profound implications, we have positioned ourselves as champions of unwavering quality and continuity.
Amidst a world of rapidly evolving technology, we understand the importance of continuous support. Laboratories and clinics depend on knowing that QuidelOrtho is by their side, enabling them to serve patients with timely, accurate results remains unfaltering.
Embrace a partnership that merges legacy with innovation, guiding healthcare forward. To learn more about QuidelOrtho and their life-saving products, simply complete our online contact form, and let's embark on a new era of excellence in diagnostics.
